ArticleCureus2024
Tobacco-Free Nicotine Pouches and Their Potential Contribution to Tobacco Harm Reduction: A Scoping Review.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Evaluation of high-nicotine oral products shows potential to reduce tobacco-related harm by offering satisfying alternatives.Scientific reports · 2025Trial
- A Narrative Review of the Potential Impact of Next-Generation Tobacco and Nicotine Products on Cardiovascular Health.Cureus · 2026Review
- Development of a model to predict nicotine pharmacokinetics from oral nicotine pouches.Scientific reports · 2026Article
- Texture Hardness and Thermomechanical Properties of Nicotine Gum Products.Journal of texture studies · 2026Article
- Marketing of oral nicotine pouches on Malaysian social media and e-commerce websites.Tobacco induced diseases · 2026Article
- Research on the safety risk of oral nicotine products and its prospects.Current research in toxicology · 2026Review
- Exploring #Zyn-Related Video Content Posted by Zynfluencers on TikTok.Substance use & misuse · 2026Article
- Nicotine pouch pharmacokinetics compared to smoked tobacco: A systematic review and meta-analysis.Drug and alcohol dependence reports · 2025Review
- Use of nicotine pouches among adults who currently or formerly smoked cigarettes and/or vaped nicotine: findings from the 2022 and 2024 US ITC smoking and vaping surveys.Tobacco control · 2025Article
- Evaluation of Factors Impacting Nicotine Permeation in Oral Nicotine Pouch Products.ACS omega · 2025Article
- Physiological and subjective effects of an oral nicotine pouch in people who use smokeless tobacco.Experimental and clinical psychopharmacology · 2025Article
- Article
- Randomized crossover clinical studies to assess abuse liability and nicotine pharmacokinetics of Velo Oral Nicotine pouches.Frontiers in pharmacology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tobacco harm reduction (THR) refers to strategies designed to reduce the health risks associated with tobacco smoking but may involve continued use of nicotine and/or tobacco. Next-generation products (NGPs) are a THR alternative as they do not burn tobacco or produce smoke and deliver nicotine and have fewer and substantially lower levels of harmful chemicals compared to cigarettes. Tobacco‑free nicotine pouches (TFNPs) are an emerging category of nicotine‑containing oral products that do not combust or contain tobacco leaf. Similar to Swedish snus, TFNPs are placed between a user's lip and gum, and nicotine is absorbed through the oral mucosa rather than being inhaled. The aim of this scoping review was to systematically collate and evaluate published scientific evidence (cut‑off of 31 May 2023) identified from bibliometric databases investigating the potential of TFNPs to contribute to THR. Overall, studies examining chemical constituents indicated that the use of TFNPs may result in lower exposure to toxicants than other tobacco or nicotine-containing products, both combustible and non‑combustible. This reduction in toxicant exposure has been demonstrated by multiple human biomarker studies and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.